Skip to main content

Table 2 Number need to harm (NNH) to each adverse event assessed in the meta-analysis.

From: Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

  Rimonabant treated Event Placebo treated Event CER (%) EER (%) NNH
Any adverse event
   Rimonabant 5 mg 2883 2364 1770 1434 81 82 102
   Rimonabant 20 mg 3393 2861 2292 1829 80 84 22
   Total 6276 5225 4062 3263 80 83 34
Serious adverse events
   Rimonabant 5 mg 2883 149 1770 79 4 5 142
   Rimonabant 20 mg 3393 207 2292 123 5 6 136
   Total 6276 356 4062 202 5 6 143
Discontinuation due to adverse events
   Rimonabant 5 mg 2883 232 1770 125 7 8 102
   Rimonabant 20 mg 3815 501 2708 206 8 13 18
   Total 6698 733 4478 331 7 11 28
Discontinuation due to psychiatric adverse events
   Rimonabant 5 mg 2883 81 1770 42 2 3 229
   Rimonabant 20 mg 3815 230 2708 72 3 6 30
   Total 6698 311 4478 114 3 5 48
Discontinuation due to neurologic adverse events
   Rimonabant 5 mg 2883 26 1770 13 1 1 597
   Rimonabant 20 mg 3684 78 2581 25 1 2 87
   Total 6567 104 4351 38 1 2 141
  1. CER, control event rate; EER, experimental event rate.